ATTAIN Outcomes
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants with Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
- Stage
- inclusie
- Medicine
- Orforglipron
- Population
- ASCVD
- Phase
- III
- First Patient In
- 10 July 2026
- Last Patient In
- 2 June 2027
- Last Patient Last Visit
- 18 September 2030
Inclusion period, 324 days remaining
National Lead
dr. S. Koudstaal
Cardioloog
Study Director
dr. J Jaspers Focks
Cardioloog
Office Contact
